Trials / Withdrawn
WithdrawnNCT01058317
Propranolol Administration in Pediatric Patients With Recurrent Respiratory Papillomatosis
- Status
- Withdrawn
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Massachusetts Eye and Ear Infirmary · Academic / Other
- Sex
- All
- Age
- 1 Year – 10 Years
- Healthy volunteers
- Not accepted
Summary
Juvenile onset recurrent respiratory papillomatosis (JORRP) is a rare, difficult to treat, benign tumor of the pediatric airway. Current therapy is mainly surgical, but in a significant portion of patients adjuvant therapy is required to control the disease process. Although multiple adjuvant medical therapies have been tried, success has been limited. We have seen some success in a limited amount of patients using orally administered propranolol. Our goal is to enroll a larger cohort of patients to determine the effectiveness of propranolol as an adjuvant therapy for JORRP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Propranolol | Propranolol 2mg/kg divided twice daily |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2010-09-01
- Completion
- 2010-09-01
- First posted
- 2010-01-28
- Last updated
- 2013-11-21
Source: ClinicalTrials.gov record NCT01058317. Inclusion in this directory is not an endorsement.